Eli Lilly Signs an Agreement with Thermo Fisher to Develop CDx for its Selpercatinib (LOXO-292)

Eli Lilly Signs an Agreement with Thermo Fisher to Develop CDx for its Selpercatinib (LOXO-292)

Shots:

  • The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with Lilly’s LOXO-292
  • Thermo Fisher will retain rights to commercialize its test in all markets including the US, EU and Japan. Post validation, Thermo Fisher will submit sPMA to the US FDA to widen clinical use of its Oncomine Dx Target Test
  • LOXO-292 is an oral RET inhibitor being evaluated in P-I/II study for advance cancers harboring RET alterations. Oncomine Dx Target Test is a next-generation sequencing-based test, approved in the US FDA in 2017 and approved for reimbursement by MHLW in Japan

Click here to­ read full press release/ article | Ref: Thermo Fisher | Image: Echolive